Highlights Molecular Templates, Inc.

Equities

MTEM

US6085502085

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-29 pm EDT			5-day change	1st Jan Change
1.73 ^USD	+1.47%		+15.33%	-53.62%

Apr. 12	Molecular Templates, Inc. Announces Cessation of Maurizio Voi as Chief Medical Officer, Effective April 30, 2024	CI
Apr. 09	Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Molecular Templates, Inc. Presents Interim Data from Mt-6402 Phase I Study in Patients with Pd-L1+ Solid Tumors At the 2024 American Association for Cancer Research Annual Meeting	Apr. 09	CI
Molecular Templates, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Molecular Templates, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 29	CI
Molecular Templates, Inc. Provides Interim Update	Mar. 04	CI
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q3 Revenue $6.8M	Nov. 13	MT
Molecular Templates, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors	Nov. 02	CI
Reverse Split: 1 of 15	23-08-13	FA
Molecular Templates' Board Approves 1-for-15 Reverse Stock Split	23-08-11	MT
Molecular Templates, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q2 Revenue $6.9M	23-08-10	MT
Molecular Templates Says US FDA Removed Partial Clinical Hold on Patient Enrollment for Phase 1 Multiple Myeloma Study	23-06-01	MT
Molecular Templates, Inc. Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma	23-06-01	CI
Molecular Templates, Inc. to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology Annual Meeting	23-05-26	CI
Molecular Templates, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Earnings Flash (MTEM) MOLECULAR TEMPLATES Reports Q1 Revenue $36.6M	23-05-15	MT
Molecular Templates Says FDA Placed Partial Clinical Hold on Phase 1 Study of MT-0169 Due to Cardiac Adverse Events	23-04-10	MT
Molecular Templates, Inc. Announces Investigational New Drug Application Acceptance by United States Food and Drug Administration for MT-8421 ETB Program Targeting CTLA-4	23-03-09	CI
Molecular Templates, Inc. to Present Interim Results on MT-5111 at the 45th Annual San Antonio Breast Cancer Symposium and Participate at the 64th American Society of Hematology Annual Meeting	22-12-02	CI
Molecular Templates, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Molecular Templates, Inc.

Equities

MTEM

US6085502085

Highlights

Filters